Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
Ab191965-100μg
|
100μg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$59.90
|
|
|
Ab191965-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$289.90
|
|
|
Ab191965-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$739.90
|
|
|
Ab191965-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$1,189.90
|
|
Purity≥95% (SDS-PAGE&SEC-HPLC); Endotoxin Level<1.0 EU/mg; Human IgGIgG1-CS; CHO; ELISA, Flow Cytometry, Functional assay, Animal Model; Unconjugated
| Product Name | Brolucizumab (anti-VEGFA) - Primary antibody, specific to VEGFA, Human IgG1-CS |
|---|---|
| Synonyms | Folliculostellate cell-derived growth factor antibody | Glioma-derived endothelial cell mitogen antibody | MGC70609 antibody | MVCD1 antibody | Vascular endothelial growth factor A antibody | vascular endothelial growth factor A121 antibody | vascular end |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Biochemical and Physiological Mechanisms | Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 re |
| Host species | Human |
| Specificity | VEGFA |
| Conjugation | Unconjugated |
| Grade | Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Product Description |
Brolucizumab (anti-VEGFA) is a single-chain anti-VEGF-A antibody fragment. Brolucizumab (anti-VEGFA) can be used for the research of cancer. |
| Isotype | Human IgG1-CS |
|---|---|
| SDS-PAGE | 52.04 kDa |
| Purification Method | Protein A purified |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 1531589-13-5 |
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Brolucizumab (anti-VEGFA) (Ab191965) - ELISA
Immobilized Recombinant Human VEGF protein (rp155965) at 1.0 μg/mL can bind Brolucizumab (anti-VEGFA) (Ab191965) with the EC₅₀ of 86.34 ng/mL.
Brolucizumab (anti-VEGFA) (Ab191965) - SEC
The purity of Brolucizumab (anti-VEGFA) (Ab191965) is more than 95% verified by HPLC.
Starting at $66.90
Starting at $109.90
Starting at $66.90
Starting at $66.90